company background image
AGIO logo

Agios Pharmaceuticals NasdaqGS:AGIO Stock Report

Last Price

US$29.24

Market Cap

US$1.6b

7D

-3.3%

1Y

29.7%

Updated

28 Mar, 2024

Data

Company Financials +

Agios Pharmaceuticals, Inc.

NasdaqGS:AGIO Stock Report

Market Cap: US$1.6b

AGIO Stock Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

AGIO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Agios Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agios Pharmaceuticals
Historical stock prices
Current Share PriceUS$29.24
52 Week HighUS$35.50
52 Week LowUS$19.80
Beta0.84
1 Month Change-16.00%
3 Month Change31.30%
1 Year Change29.67%
3 Year Change-44.43%
5 Year Change-56.00%
Change since IPO-6.52%

Recent News & Updates

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Recent updates

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06
We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18
Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios adds more than 13% after Novo deal to acquire rival Forma

Sep 01

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Aug 04

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Jul 26

Agios Pharmaceuticals appoints new board chair, CEO

Jul 12

Agios: Approved Product, Upcoming Catalysts

May 10

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 10
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Agios Pharmaceuticals With FDA Approval Is A Buy

Feb 23

Agios Before The February PDUFA

Jan 20

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced

Sep 07

Agios submits mitapivat application in U.S. for pyruvate kinase deficiency

Jun 21

Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

May 13
Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals Q1 2021 Earnings Preview

Apr 28

Shareholder Returns

AGIOUS BiotechsUS Market
7D-3.3%0.9%0.4%
1Y29.7%10.3%28.8%

Return vs Industry: AGIO exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: AGIO matched the US Market which returned 28.8% over the past year.

Price Volatility

Is AGIO's price volatile compared to industry and market?
AGIO volatility
AGIO Average Weekly Movement7.2%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: AGIO's share price has been volatile over the past 3 months.

Volatility Over Time: AGIO's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007385Brian Goffhttps://www.agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.

Agios Pharmaceuticals, Inc. Fundamentals Summary

How do Agios Pharmaceuticals's earnings and revenue compare to its market cap?
AGIO fundamental statistics
Market capUS$1.64b
Earnings (TTM)-US$352.09m
Revenue (TTM)US$26.82m

61.3x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGIO income statement (TTM)
RevenueUS$26.82m
Cost of RevenueUS$298.41m
Gross Profit-US$271.58m
Other ExpensesUS$80.50m
Earnings-US$352.09m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.27
Gross Margin-1,012.50%
Net Profit Margin-1,312.63%
Debt/Equity Ratio0%

How did AGIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.